Actively Recruiting

All Genders
ID04613089

Natural History and Long Term Clinical Assessments of All Forms of Neuronal Ceroid Lipofuscinoses Capturing Key Symptoms and Disease Progression in the International NCL DEM-CHILD Patient Database

Led by Universitätsklinikum Hamburg-Eppendorf · Updated on 2021-10-29

500

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to understand the natural history and progression of Neuronal Ceroid Lipofuscinoses (NCL), also known as Batten disease, which are rare inherited neurodegenerative disorders caused by mutations in various genes. These mutations lead to progressive loss of motor skills, cognition, vision, seizures, and behavior changes. The study seeks to document symptom development and disease progression more accurately to support testing of new experimental treatments and improve scientific knowledge. Participants include patients with genetically confirmed NCL diagnoses, covering multiple gene mutations such as CLN1 through CLN14. The study collects data through medical records, patient questionnaires, and routine clinical exams focused on motor, language, cognition, seizures, vision, and behavior. A local biorepository and an international virtual biorepository are established to facilitate access to patient samples for research. Families of deceased patients with known genetic mutations may also contribute retrospective data. During participation, researchers gather clinical information over time to identify key symptoms and develop tools for rating disease progression, with follow-up lasting up to 30 years. This includes establishing well-characterized natural history cohorts to serve as controls for future therapy trials. The study also collects and stores biological samples to support international research efforts. There is no treatment involved; instead, the focus is on observation and data collection to better understand NCL diseases.

CONDITIONS

Brief Title

Natural History and Longitudinal Clinical Assessments in NCL / Batten Disease, the International DEM-CHILD Database

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with a confirmed molecular diagnosis of a form of NCL Disease
  • Documented diagnosis of TPP1 deficiency for those in the CLN2 Disease - ERT (Brineura) Treated group
  • Previous or current treatment with intracerebroventricular enzyme-replacement therapy with cerliponase alpha allowed
  • Patients currently participating in post-marketing studies allowed in the CLN2 ERT treated group
Not Eligible

You will not qualify if you...

  • Patients with no confirmed molecular diagnosis of a form of NCL Disease

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Surveillance

Duration - Up to 30 years

Participants with genetically confirmed NCL are observed to collect natural history and clinical follow-up data to understand disease progression and key symptoms.

Periodic visits depending on individual patient assessments

Trial Site Locations

Total: 1 location

1

University Medical Center Hamburg-Eppendorf

Hamburg, Germany, 20246

Actively Recruiting

Loading map...

Research Team

M

Miriam Nickel, MD

A

Angela Schulz, MD, PhD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

14

Similar Trials

Clinical and Neuropsychological Investigations in Batten Dis...

Neuronal Ceroid Lipofuscinosis

Actively Recruiting

1 location

Foundation Fighting Blindness My Retina Tracker Registry for...

Eye Diseases Hereditary

Actively Recruiting

1 location

Investigations of Juvenile Neuronal Ceroid Lipofuscinosis (C...

Juvenile Neuronal Ceroid Lipofuscinosis (CLN3)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study.

Miriam Nickel, Alessandro Simonati, David Jacoby...

https://pubmed.ncbi.nlm.nih.gov/30119717

Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.

Michael Fietz, Moeenaldeen AlSayed, Derek Burke...

https://pubmed.ncbi.nlm.nih.gov/27553878

Retention of lysosomal protein CLN5 in the endoplasmic reticulum causes neuronal ceroid lipofuscinosis in Asian sibship.

Anne-Hélène Lebrun, Stephan Storch, Franz Rüschendorf...

https://pubmed.ncbi.nlm.nih.gov/19309691

Volumetric Description of Brain Atrophy in Neuronal Ceroid Lipofuscinosis 2: Supratentorial Gray Matter Shows Uniform Disease Progression.

U Löbel, J Sedlacik, M Nickel...

https://pubmed.ncbi.nlm.nih.gov/27231226